Presentation is loading. Please wait.

Presentation is loading. Please wait.

Paul Richards CRB Consulting Engineers PharmaForum 2011 - Portland, OR.

Similar presentations


Presentation on theme: "Paul Richards CRB Consulting Engineers PharmaForum 2011 - Portland, OR."— Presentation transcript:

1 Paul Richards CRB Consulting Engineers PharmaForum Portland, OR

2  I am not an Industrial Hygienist  I am a Chemical Engineer who is PASSIONATE about containment  Senior Process Engineer for CRB Consulting Engineers  23+ years in chemical and pharmaceutical industries ◦ Formerly Sr. Principal Engineer with Pfizer (11+ years)  Extensive capital project experience in API and OSD manufacturing facilities  Designed, installed, and tested many successful containment systems  Steering Committee - ISPE Containment CoP  Board of Directors – ISPE New England Chapter  BS Chemical Engineering / MS Management

3  What is Risk-MaPP  How Risk-MaPP relates to Containment  Practical solutions PharmaForum Portland, OR

4  A guide to managing risks associated with cross contamination  ISPE Baseline Pharmaceutical Engineering Guide ◦ Rolled out in Fall of 2010 ◦ Six years in development ◦ FDA and EMA reviewed and approved  “meant to assist pharmaceutical manufacturers in the design and construction of new and renovated facilities that are required to comply with the requirements of the US FDA.”

5 PharmaForum Portland, OR Risk-MaPP provides a scientific risk-based approach, based on ICH Q9, to manage the risk of cross contamination in order to achieve and maintain an appropriate balance between product quality and operator safety. Focus on science based risk analysis to design and operation versus emotional reactions

6 PharmaForum Portland, OR  Protecting the PATIENT through quality systems to manage the risk of cross contamination

7 PharmaForum Portland, OR

8  Mix-up ◦ Cross contamination by using wrong API, excipients, product contact materials, equipment, etc…  Equipment Retention / Residue Carryover ◦ Material that remains in product contact after cleaning due to failure or inadequate cleaning  Mechanical Transfer ◦ Particulate transfer on clothing/feet from operators and equipment alternating between 2 or more processing areas  Airborne Transfer ◦ Cross contamination via airborne migration of particulates

9 PharmaForum Portland, OR

10  cGMP versus Industrial Hygiene  Patient versus the Operator  Different exposure routes / pathways  IH monitoring targeted at worker exposure not cross contamination ◦ How do you meaningfully correlate IH data from an air sampling pump and filter?  How do you validate containment if it is a cGMP control?

11 PharmaForum Portland, OR  Sterile Manufacturing ◦ RABS ◦ Isolators  Highly hazardous (potent) compounds ◦ Containment is effective to protect workers as well as to reduce risks of cross contamination via mechanical transfer or airborne transfer

12 PharmaForum Portland, OR  Redundant electronic verification of materials  Redundant manual checks  Color coding  Bar coding and RFID of materials & equipment  Locked cages to store APIs with chain of custody  Transfer and utility connect technologies that are unique to the process  Process Analytical Technologies (ie. NIR)  Separate dispensary areas  Separate raw material staging areas

13  Clean to set limits ◦ Base limits on science, risk assessment, statistical analysis ◦ Cleaning validation ◦ Equipment designed for CIP ◦ On-line monitoring / PAT  Disposable product contact parts  Dedicated product contact parts PharmaForum Portland, OR

14

15  Limit transfer of compounds between suites ◦ ie. High Shear Granulation, Milling, and Drying in same suite  Segregate work areas to a single product  Contain at the Source  Close process systems  Room airflow  Airlocks  Gowning procedures  Wipe down protocols for mobile equipment  Clean mobile equipment in processing room  Misting showers  Cleaning bays with dirty / clean pass through

16 PharmaForum Portland, OR  Contain at the Source  Close process systems  Room airflow  Airlock separation to corridor  Gowning procedures  Wipe down protocols  Misting showers  Room differential pressures  High room air change rates

17 Contain at the source Avoid technique dependant systems Focus on transfer systems Design below the OEL / ADE Consider ergonomics, cleaning, sampling, waste, material compatibility Provide redundancy / secondary containment Engineer out the reliance on PPE

18 PharmaForum Portland, OR

19

20

21 OEL (μg/m 3 ) Local exhaust ventilation Crossflow booth Downflow booth Cone Valve Split Butterfly Valves Split Butterfly (Glatt SKS / Buck TC) Rapid Transfer Ports (RTPs) 10,000 1, Bag Technology OEB VOEB IOEB IIOEB IIIOEB IV Split Butterfly Valves with air extraction HicoFlex / EziDock CSV4

22 Well proven in industry Performance: < 0.1 μg/m 3 Consists of an alpha (active) port attached to an isolator and a beta (passive) port connected to the portable container The beta is docked and locked to the alpha by rotation before the door can be opened Requires an isolator Vendors La Calhene Applied Containment Engineering Central Research Labs

23

24

25 Same basic technology at RTP, but passive attaches to equipment Active fitted with a purpose made glove bag Active made in HDPE to keep light weight Passive flange or bolted Adapt passive with sight glass Pressure cap provides 6 bar-g design Active $12,000 Passive $ 6,000 (SS) Vendor – Heaton Green Containment

26

27 Primary Vendors GEA Buck ValveGEA Buck Valve Charge PointCharge Point GlattGlatt AndocksystemeAndocksysteme Types of Split Butterfly Valves StandardStandard With air extraction shroudWith air extraction shroud Air or Liquid Wash systemsAir or Liquid Wash systems Pressure rated or notPressure rated or not Primary concern with split butterfly valves! material on the faces of the valves after undockingmaterial on the faces of the valves after undocking

28

29 PharmaForum Portland, OR

30

31  Perform risk assessment to identify steps and controls, prioritize level of risk, and determine corrective actions  FMEA format for risk assessment ◦ Severity – the impact on the patient ◦ Occurrence – how often this effect takes place ◦ Detection – how easily the failure can be detected  Multiply each factor for a resulting risk priority number (RPN) ◦ S x O x D = RPN  Set limits for RPNs ◦ Acceptable ◦ Investigate and remedy ◦ Requires immediate attention

32 PharmaForum Portland, OR

33

34  The FDA is on board with Risk-MaPP  The regulations have not changed, but the FDA will expect all manufacturers’ to “Show us your scientifically sound assessment” to prevent cross contamination and to “justify the level of controls”  There are many common engineering controls to reduce risks of potential cross contamination and operator exposure  Understand and document your risks and your controls

35 PharmaForum Portland, OR


Download ppt "Paul Richards CRB Consulting Engineers PharmaForum 2011 - Portland, OR."

Similar presentations


Ads by Google